MRI of Myocardial Infarction

NCT03531151 | Completed

• 1 other identifier: 827697
• Study Type: observational
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

Heart failure (HF) is an enormous health burden affecting approximately 5.1 million people in the US and is the cause of 250,000 deaths each year. Approximately 50% of HF is caused by myocardial ischemia and requires immediate restoration of coronary blood flow to the affected myocardium. However, the success of reperfusion is partly limited by intramyocardial hemorrhage, which is the deposition of intravascular material into the myocardium. Hemorrhagic reperfusion injury has high prevalence and patients have a much greater risk of adverse left ventricular remodeling, risk of fatal arrhythmia, impaired systolic function and are hospitalized at a greater rate. Recent magnetic resonance imaging techniques have improved assessment of reperfusion injury, however, the association between MRI contrasts and reperfusion injury is highly unclear, and lacks specificity to IMH. Improved imaging of IMH and accurate knowledge about its spatial and temporal evolution may be essential for delivery of optimal medical therapy in patients and critical to identify patients most at risk for adverse ventricular remodeling. The overall goal is to investigate the magnetic properties of hemorrhage and develop MRI techniques with improved specificity to hemorrhage. New MRI techniques permit noninvasive assessment of the magnetic susceptibility of tissues and can target tissue iron. Therefore, the investigators hypothesize that MRI imaging of myocardial magnetic susceptibility can map hemorrhagic myocardium. The investigators will perform a longitudinal observational study in patients after reperfusion injury to validate these methods, compare the methods with conventional MR contrasts and develop MR methods for imaging humans.

Conditions

Myocardial Infarction; Myocardial Ischemia; Myocardial Injury; Myocardial Fibrosis; Myocardial Reperfusion Injury; Myocardial Edema; Myocardial Necrosis; Heart Failure; Ischemic Heart Disease; Ischemic Cardiomyopathy; Hemorrhage

Outcome Measures

Primary Outcomes (1)

• ejection fraction

  <36 hours to >6 months

Secondary Outcomes (2)

• relaxation times

  <36 hours to >6 months

• extracellular volume fraction

  <36 hours to >6 months

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population specific to this project are ST-elevated myocardial infarction (STEMI) patients being treated with reperfusion therapy.

You may qualify if:

• Between the ages of 18 and 80
• Patients must be able to read and understand English
• Participants must sign the informed consent form
• Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
• ST elevation detected on ECG

You may not qualify if:

• contraindications to cardiac MRI, including claustrophobia
• advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
• presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
• pregnancy
• personal or family history of hypertrophic cardiomyopathy
• inability to provide informed consent
• history of seizure disorder

Sponsors & Collaborators

• University of Pennsylvania: lead

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Heart Failure; Hemorrhage

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Cardiomyopathies; Reperfusion Injury; Postoperative Complications

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2018
• First Posted: May 21, 2018
• Study Start: April 1, 2018
• Primary Completion: March 31, 2025
• Study Completion: March 31, 2025
• Last Updated: September 8, 2025

Record last verified: 2025-09

Locations

US (1)